False-negative hepatitis B virus (HBV) surface antigen in a vaccinated dialysis patient with a high level of HBV DNA in the United States

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 820-822

  Foy, Matthew C ^a   Thio, Chloe L ^a   Hwang, Hyon S ^a   Saulynas, Melissa ^a   Hamilton, James P ^a   Fine, Derek M ^a   Atta, Mohamed G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CHEMOLUMINESCENCE; CHILL; CONSENSUS SEQUENCE; DYSPNEA; FALSE NEGATIVE RESULT; FEMALE; FEVER; GENE AMPLIFICATION; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MICROPARTICLE ENZYME IMMUNOASSAY; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; UNITED STATES;

DNA, VIRAL; FALSE NEGATIVE REACTIONS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MIDDLE AGED; RENAL DIALYSIS; UNITED STATES;

EID: 84860345110     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05696-11     Document Type: Article

References (20)

1. Ayres A, Locarnini S, Bartholomeusz A. 2004. HBV genotyping and analysis for unique mutations. Methods Mol. Med. 95:125-149.
2. Bichko V, Pushko P, Dreilina D, Pumpen P, Gren E. 1985. Subtype ayw variant of hepatitis B virus. DNA primary structure analysis. FEBS Lett. 185:208-212. (Pubitemid 15058215)
3. Carman WF, et al. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329. (Pubitemid 20264145)
4. Centers for Disease Control and Prevention. 2001. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recommend. Rep. 50(RR-5):1-43.
5. Coleman PF, Chen YC, Mushahwar IK. 1999. Immunoassay detection of hepatitis B surface antigen mutants. J. Med. Virol. 59:19-24. (Pubitemid 29362160)
6. Echevarria JM, Avellon A. 2008. Improved detection of natural hepatitis B virus surface antigen (HBsAg) mutants by a new version of the VITROS HBsAg assay. J. Med. Virol. 80:598-602. (Pubitemid 351358555)
7. Ghany MG, et al. 1998. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213-222.
8. Gibb R, Nimmo GR, O'Loughlin P, Lowe P, Drummond D. 2007. Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection. J. Med. Virol. 79:351-355. (Pubitemid 46355433)
9. Goldstein ST, et al. 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34:1329-1339. (Pubitemid 41819540)
10. Kim KH, et al. 2003. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J. Med. Virol. 71:367-375.
11. La'ulu SL, Roberts WL. 2006. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am. J. Clin. Pathol. 125:748-751.
12. Launay O, et al. 2011. High levels of serum hepatitis B virus DNA in patients with "anti-HBc alone": Role of HBsAg mutants. J. Viral Hepat. 18:721-729.
13. Minuk GY, et al. 2004. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 40:1072-1077. (Pubitemid 39425562)
14. Moraleda G, et al. 2006. De novo HBV infection caused by an anti-HBc positive donor in a vaccinated liver transplant recipient in spite of anti-HBs response. Am. J. Transplant. 6:438-440. (Pubitemid 43382187)
15. Muhlbacher A, et al. 2008. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med. Microbiol. Immunol. 197:55-64. (Pubitemid 350161754)
16. Raimondo G, et al. 2008. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49:652-657.
17. Shire NJ, et al. 2007. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J. Acquir. Immune Defic. Syndr. 44:309-314. (Pubitemid 46328348)
18. Tapper EB, Lau DT. 2011. The need for clarity in occult HBV infection. J. Viral Hepat. 18:673-674.
19. Weber B. 2005. Genetic variability of the S gene of hepatitis B virus: Clinical and diagnostic impact. J. Clin. Virol. 32:102-112. (Pubitemid 40093960)
20. Weinbaum CM, et al. 2008. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recommend. Rep. 57:1-20.